Kangstem Biotech

KOR | ENG

주메뉴

Company
- Company
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- About Us
- Kangstem Biotech
- Global R&D Center
- Stem Cell GMP Center
- Welcome Message
- Vision & Mission
- History
- Location
Business
- Business
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Stem Cell Therapy
- FURESTEM-OA Kit Inj.
- FURESTEM-AD® Inj.
- FURESTEM-RA® Inj.
- Advanced Regenerative Medicine
- Organoid
- Organoid
- Skin Organoid
- Islet Organoid
- CDMO Business
- CDMO
- JUVENTAS
- Stem Cell Culture Business
- Health&Beauty Business
R & D
- R & D
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Core Technology
- Umbilical Cord Blood Stem Cell
- High-Compact Technology Strategy
- R&D Achievements
Investors
- Investors
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Notice
- PR
- Press Release
- PR Resource Center

Core Technology

R&D Achievements

Kangstem Biotech is advancing innovative therapies through its cell therapy and organoid platforms, with a strong foundation in scientific evidence and clinical potential.

R&D Achievements

2025.02

Primed Mesenchymal Stem Cells by IFN-γ and IL-1β ameliorate Acute Respiratory Distress Syndrome through enhancing homing effect and immunomodulation

Journal : Biomolecules & Therapeutics

2024.05

Guidelines for Manufacturing and Application of Organoids: Skin

Journal : International Journal of Stem Cells

2022.11

LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells

Journal : PLOS ONE

2021.12

Immunomodulatory effect of epidermal growth factor secreted by human umbilical cord blood-derived mesenchymal stem cells on atopic dermatitis

Journal : International Journal of Stem Cells

2021.10

Combined Mesenchymal Stem Cells and Cartilage Acellular Matrix Injection Therapy for Osteoarthritis in Goats

Journal : Tissue Eng Regen Med

2021.08

Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling

Journal : Stem Cell Research & Therapy

2020.12

Extracellular Vesicles from SOD3-Transduced Stem Cells Exhibit Improved Immunomodulatory Abilities in the Murine Dermatitis Model

Journal : Antioxidants (Basel)

2020.12

Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response

Journal : Biomedicine & Pharmacotherapy

2020.09

Combinatorial Strategies for Long-term Control of Human Immunodeficiency Virus Infection

Journal : AIDS Reviews

2020.08

Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells

Journal : Stem Cell Reviews and Reports

1 2 3 4

Company

About Us

Business

Stem Cell Therapy

Organoid

CDMO Business

Health&Beauty Business

R&D

Core Technology

Investors

Notice